Moderate-to-Severe Asthma Clinical Trial
Official title:
A Prospective, Observational, Multicentre Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China
This is a Prospective, Observational, Multicentre Study to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in China. Sponsor by Astrazeneca Investment(China) Co., LTD.
This is a prospective, observational, multicentre study. Approximately 500 moderate-to-severe asthma patients from 30 sites across China. Patients will be treated following routine clinical practice. Study measures will be collected at week 0, week 12 and week 24. The primary objective of PRESENT study is to describe treatment pattern changes of uncontrolled moderate-to-severe asthma patients in China. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01603277 -
Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
|
Phase 2 |